ASX Announcement

Results of Annual General Meeting

Perth, Australia; 6 November 2026: Orthocell Limited (ASX: OCC, "Orthocell" or "the Company") advises that its Annual General Meeting of Shareholders was held today at 10.00 am AWST.

The resolutions were voted in accordance with the Notice of Annual General Meeting and Supplementary Notice of Annual General Meeting previously advised to the Australian Securities Exchange, with all resolutions being carried on a poll.

Resolution 4 (Amendment to Constitution) was carried by a sufficient majority as a special resolution.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries	Media enquiries	Investor enquiries
Paul Anderson Orthocell Limited CEO and MD P: +61 8 9360 2888 E: paul.anderson@orthocell.com	**Haley Chartres** **H^CK Director** P: +61 423 139 163 E: haley@hck.digital	**Shaun Duffy** **VECTOR Advisors** P: +61 404 094 384 E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate, "expect," "intend," "may," "plan," "predict," "project," "target, "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Results of Meeting

Orthocell Limited

Annual General Meeting

Friday, 06 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Non-binding Resolution to adopt Remuneration Report	P	45,829,647 78.26%	12,534,652 21.40%	243,538	198,047 0.34%	48,198,273 78.27%	13,384,517 21.73%	204,288	-
2 Re-election of Mr John Van Der Wielen as a Director	P	65,252,677 96.23%	2,306,956 3.40%	1,037,767	249,886 0.37%	68,987,091 96.76%	2,306,956 3.24%	1,037,767	Carried
3 Re-election of Dr Ravi Thadhani as a Director	P	65,711,800 96.90%	1,849,194 2.73%	1,036,406	249,886 0.37%	69,446,214 97.41%	1,849,194 2.59%	1,036,406	Carried
4 Amendment to Constitution to adopt proportional takeover approval provisions	P	61,777,649 91.70%	5,251,024 7.79%	1,477,027	341,586 0.51%	65,628,763 92.59%	5,251,024 7.41%	1,452,027	Carried
5 Issue of Short-Term Performance Rights to Mr Paul Anderson or his nominee(s)	P	47,931,296 78.79%	12,658,032 20.81%	63,401	246,769 0.41%	50,584,238 78.92%	13,507,897 21.08%	264,151	Carried
6 Approval of potential termination benefits in relation to Short-Term Performance Rights to be issued to Mr Paul Anderson or his nominee(s)	P	46,950,551 78.16%	12,897,241 21.47%	211,501	224,071 0.37%	49,041,501 78.11%	13,747,106 21.89%	475,951	Carried
7 Appointment of Auditor	P	64,221,814 95.35%	2,882,609 4.28%	1,494,010	248,853 0.37%	67,955,195 95.93%	2,882,609 4.07%	1,494,010	Carried